Screening and earlier detection are key in the fight against cancer. Exact Sciences is at the forefront of multi-cancer earlier detection, which has the power to close the screening gap and to get at that 70% of cancers that currently do not have routine screening options. Jake Orville, General Manager of Pipeline at Exact Sciences, shares his perspective on the latest innovations in multi-cancer earlier detection and other emerging technologies and talks about Exact Sciences’ proprietary testing platform, which can identify the minute fragments of circulating tumor DNA and proteins expressed that are causative across many types of cancer.
Jake Orville has 20+ years of diagnostic, life science and medical device senior management experience within both established and emerging markets. As the General Manager of Pipeline at Exact Sciences, Jake leads the company’s efforts to develop and advance solutions for earlier detection and life changing answers across the cancer continuum. Under Jake’s leadership, Pipeline is taking the same innovative problem-solving approach that resulted in the multitarget stool DNA test (Cologuard) to tackle a wide array of cancer screening challenges. Prior to Exact Sciences, Jake co-founded Cleveland HeartLab, Inc. (CHL) and served as the CEO from inception to exit.